CLDX Celldex Therapeutics
Celldex Therapeutics earnings company data as of 4:46 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 9 Nov | EPS | -1.01 | — | — |
| Rev | $883.2K | — | — |
Insider trades
Open-market buys and sales by CLDX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $1.3M sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Freddy A. Jimenez SVP & General CounselSale$121K 4,166 shares at $29.10 12% of stakeTraded Dec 4, 2025 Filed Dec 8, 2025
-
Richard M. Wright InsiderSale$1.2M 49,298 shares at $24.00 70% of stakeTraded Nov 13, 2025 Filed Nov 17, 2025
Also filed in the last 12 months, not counted as buying or selling: 6 option exercises.
SEC filings
Recent issuer filings from EDGAR, 22 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | FORM DEF 14A | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-K | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.